The Danish pharma giant is looking beyond trial results that showed semaglutide, the key ingredient in its weight-loss drugs, was not effective in slowing the progression of Alzheimer’s disease https://t.co/6rdUdPRnj0 ...

Novo Nordisk shares fell sharply after it said a pill with the key ingredient in Ozempic and Wegovy didn’t slow Alzheimer’s disease in two late-stage clinical trials https://t.co/tyGUAbg19E ...

Sleep is important to our health but could it help prevent the onset and progression of Alzheimer’s disease? Bloomberg Prognosis asks the question.... https://t.co/8C3BPD9AAe ...

Roche Holding plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, its latest investment in one of the most failure-prone areas of drugmakin. https://t.co/1Rz3issNvH ...

Regulatory Approval - Lilly's Alzheimer's disease drug Kisunla receives backing from EU regulators for use in a specific patient group [1]

Seoul-based Illimis Therapeutics has raised 58 billion won ($42 million) to fund its research into treatments for Alzheimer’s disease and expand into immune diseases.https://t.co/QiTtfEYSjy https://t.co/XdRh7oCqF8 ...

The average age when people in the Richardson family who carry a gene mutation start to show symptoms of Alzheimer’s disease is 39. Three young siblings in the family hope to change that. https://t.co/4AKaFgvboQ ...

The average age when people in the Richardson family who carry a gene mutation start to show symptoms of Alzheimer’s disease is 39. Three young siblings in the family hope to change that. https://t.co/EG83x9t9Fb ...

The average age when people in the Richardson family who carry a gene mutation start to show symptoms of Alzheimer’s disease is 39.Three young siblings in the family hope to change that. 🔗 https://t.co/l919k115HF https://t.co/3xnvaD5oST ...